• Financial performance: Wockhardt reported 26% topline growth in the latest quarter, maintained positive profit after tax for the past 12 months, and expanded EBITDA margins to 17% with expectations of further improvement.
• Zaynich launch timelines: The drug is slated for introduction in India by late this year or early next year and in the US by Q1 next year, with revenue anticipated to ramp up sharply 12 to 18 months post-launch after an initial 4- to 6-month medical pre-launch outreach.
• Miqnaf market expansion: Following the removal of DCGI supply restrictions, adoption is expected to rise significantly as 80% of pneumonia cases are treated in outpatient clinics rather than hospitals for this three-day tablet regimen.
• Antibiotic franchise strategy: Holding US FDA Fast Track status for six molecules, the company plans to spend three to four years establishing Zaynich globally while advancing candidates like molecule 6777, which is entering Phase 2 clinical trials.
• Diabetes segment outlook: The insulin and biosimilars business doubled last quarter and is targeted to sustain 40% plus growth over the next several years through capacity expansions, new insulin analogs, and planned Western market entry in roughly three years.